Congratulations | NSW Advanced Trainee Research Showcase

The NSW Advanced Trainee Research Showcase was held via Zoom on Wednesday 2 February 2022.

Congratulations to the winner:
Dr Karan Rao who presented, “Key demographic, clinical and electrocardiographic predictors of troponin positive chest pain with unobstructed coronary arteries.”

The runner-up was Dr Christian Said for his presentation, “Prevalence of hand dysfunction after distal transradial artery access for coronary angiography and percutaneous coronary intervention.”

Thank you to our NSW CSANZ Board Member, Prof Liza Thomas, who organised the event and to the judges, Prof Len Kritharides, Prof Chris Semsarian and Prof Kazuki Negishi.

The presentations were followed by a talk on myocarditis following mRNA COVID vaccines by A/Prof Raj Puranik.

The inaugural Graeme Sloman AO Cardiology Trainee Research Prize

The Victorian division of CSANZ have decided to increase the profile of their annual trainee research prize, and simultaneously recognise and pay tribute to, an outstanding Victorian cardiologist. The first cardiologist to be recognised in this way is Dr Graeme Sloman AO.

Dr Sloman was chosen for his contributions to the way cardiology and patient care is delivered in Australia, to this day. He set up the first Coronary Care Unit in 1964 at the Royal Melbourne Hospital and was instrumental in the evolution of the ambulance service to include the MICA (Mobile Intensive Care Ambulance) that benefits our patients today. This was recently celebrated by Ambulance Victoria on the 50 year anniversary of the Victorian MICA service (https://www.ambulance.vic.gov.au/celebrating-50-years-of-world-class-mica-service-for-victorians/).

A/Prof Dominica Zentner said, “We were fortunate to have both Graeme and his wife Bella join us for the announcement of the ” Graeme Sloman Cardiology Trainee Research Prize “  at the Victorian AGM meeting on Wednesday 27th October, held via Zoom”.

The inaugural Graeme Sloman AO Cardiology Trainee Research prize was awarded to Dr Anna Beale, who presented her work on “The gut microbiome of heart failure with preserved ejection fraction”.

Dr Graeme Sloman AO (CSANZ Life Member) is pictured here with A/Prof Dominica Zentner, Chair, Victorian Regional Committee

 

HLC launches on YouTube with Vascular Ageing Panel discussion

Heart, Lung and Circulation’s Special Issue on Vascular Ageing (November 2021 edition) is now accessible online at www.heartlungcirc.org.

Heart, Lung and Circulation launches on Elsevier Journal’s YouTube Channel with a special interview with the Guest Editors of the Edition. Dr Rachel Climie (Menzies Institute for Medical Research, TAS), A/Prof Jonathan Mynard and A/Prof Salvatore (Sal) Pepe, (both from Murdoch Children’s Research Institute, VIC) provide a brief introduction to the Edition.

The editors explain the concept of Vascular Ageing (Is your vascular age the same as your calendar age?), how Vascular Age might be measured and what might modify it. They highlight some of the contributions in the edition for the viewer’s attention.

Watch it here: https://www.youtube.com/watch?v=hyX9VoLNcok

Why SGLT2 inhibitors should be used in Heart Failure – Live Panel Discussion

In case you missed the cardiologist expert live panel discussion between CSANZ members (listed below) and Prof Meg Jardine, nephrologist.

  • A/Prof John Amerena, Director of the Geelong Cardiology Research Unit
    Department of Epidemiology and Preventative Medicine at Monash University.
  • Prof Meg Jardine, Professor and Director, NHMRC Clinical Trials Centre, Faculty of Medicine and Health(FMH) Senior Staff Specialist, Concord Repatriation General Hospital
  • Prof Andrew Coats, AO, Director of the Monash Warwick Alliance and Academic Vice-President, Monash and Warwick Universities.
  • Prof David Kaye, NHMRC Senior Principal Research Fellow, Director of the Department of Cardiology at The Alfred Hospital, and Head of the Heart Failure Research group at the Baker Institute.

Follow this link to the Free On Demand version on how SGLT2 inhibitors can provide beneficial effects in people with heart failure.

(Registration is required to access)

 

 

2021 R T Hall Lecture presented by Dr Helen Hobbs

The 2021 R T Hall Lecture was presented by Dr Helen Hobbs at the 2021 CSANZ ASM.   Dr Hobbs is Director of the Eugene McDermott Center for Human Growth and Development and a professor of internal medicine and molecular genetics at The University of Texas Southwestern Medical Center.

2021 RT Hall Lecture: Human genetics reveals new therapeutic targets for cardiometabolic disorders

View Dr Hobbs’ presentation here – follow link to the CSANZ ASM video on Vimeo.

Dr Helen H. Hobbs attended Stanford University and then Case Western Reserve Medical School. She trained in internal medicine at Columbia-Presbyterian Hospital before completing her medical training at the University of Texas Southwestern Medical Center. She trained in the laboratory of Drs. Joseph Goldstein and Michael Brown and then joined the faculty of UT Southwestern in 1987. Together with Jonathan C. Cohen, she has identified new sequence variations/genes contributing to differences in plasma levels of LDL-cholesterol and triglyceride (TG). These studies have provided new insights into the pathogenesis of coronary heart disease and led to the development of two new lipid-lowering therapies. She also has identified genetic differences contributing to susceptibility and resistance to fatty liver disease. Gene identification is just the starting point for her studies. She has performed functional studies to characterize the pathways and processes that are altered by the defective genes she identifies. She was elected to the National Academy of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences. Among the prizes she has received are the Breakthrough Prize in Life Sciences, the Grand Prix Award from the Institute of France, and the Harrington Prize for Innovation and Medicine.

2021 Kempson Maddox Lecture presented by Prof Diane Fatkin

The 2021 Kempson Maddox Lecture was presented by Prof Diane Fatkin at the 2021 CSANZ ASM. Prof Fatkin is the  Head of the Sr Bernice Research Program in Inherited Heart Diseases, in the Molecular Cardiology Division of the Victor Chang Cardiac Research Institute.

2021 Kempson Maddox Lecture:   Evolution of the genetics revolution in heart failure management.

View Prof Fatkins’ presentation here – follow link to the CSANZ ASM video on Vimeo.

Prof Diane Fatkin trained in Clinical Cardiology and Molecular Genetics and is currently Head of the Sr Bernice Research Program in Inherited Heart Diseases, in the Molecular Cardiology Division of the Victor Chang Cardiac Research Institute, Sydney. She also holds appointments as Honorary Medical Officer in the Cardiology Department, St Vincent’s Hospital, and Professor (conjoint) in the Faculty of Medicine, UNSW Sydney. Her research is focused on understanding the molecular genetic basis of inherited cardiomyopathies, with a specific interest in familial dilated cardiomyopathy and familial atrial fibrillation. This work spans from clinical and genetics studies in families with inherited cardiomyopathies to functional genomics in the cell, mouse, and zebrafish models. A major objective of the team’s research is the “bench-to-bedside” translation of new insights about disease mechanisms into personalised approaches to patient management.

Sports Cardiology by Dr Belinda Grey and A/Prof Andre Gerche

Dr Belinda Grey
A/Prof Andre La Gerche

Dr Belinda Gray 1,2       A/Prof Andre La Gerche 3,4

  1. Department of Cardiology, Royal Prince Alfred Hospital, Sydney NSW
  2. Central Clinical School, Faculty of Medicine and Health University of Sydney NSW
  3. Baker Heart and Diabetes Institute, Melbourne VIC
  4. St Vincent’s Hospital Melbourne VIC

The emerging sub-specialty of sports cardiology has been an area of significant growth in recent years with recognition that there are unique diagnostic challenges in identifying cardiac pathology and specific management considerations amongst athletes and exercise enthusiasts. Whilst there is an increased general awareness of the importance of physical activity in reducing one’s overall risk of cardiovascular disease there is also increased awareness of the potential for high level athletes to have underlying inherited or acquired cardiovascular disease that may place them at risk of adverse events during physical activity. Therefore the American College of Cardiology and the European Society of Cardiology have established their own councils for Sports Cardiology as well as developing specific sports cardiology guideline documents. There is now a recommendation from both councils, that athletes should be reviewed in a centre with specialised expertise in sports cardiology in order to minimise harm to the athlete; by ensuring diagnostic accuracy and appropriate management recommendations are implemented for sports men and women.

Athletes represent the fittest individuals in our society, yet paradoxically some studies have suggested that they are at increased risk of sudden cardiac death when compared to the general population. Up to 50% of young athlete sudden deaths are due to pre-existing cardiac conditions including inherited heart muscle and heart rhythm problems. Being able to identify those individuals who may be at risk of sudden cardiac death during exercise is only one part of practicing sports cardiology. Being able to accurately order and interpret diagnostic testing in athletes is also a key role of a sports cardiologist. There are a number of “normal” cardiac adaptations that occur in athletes. There are profound changes in cardiac structure, function and electrophysiology. The study of sizeable athletic populations are required to provide an adequate description of the spectrum of normal athletic remodelling. This is critical to enable differentiation from subtle cardiac pathology. Like all areas of cardiology, this is a niche area of knowledge that is required to best manage athletic individuals presenting with syncope, fatigue, palpitations or abnormalities on screening/ incidental findings. Clinicians working in this field will be all too familiar with a simple observation (profound bradycardia, for example) leading to a cascade of tests, an incorrect diagnosis of pathology and exclusion from sport. Or the corollary, such as the athlete with inferolateral T-wave inversion and wall thickness increase that is diagnostic of hypertrophic cardiomyopathy but is incorrectly labelled ‘athlete’s heart’ because of vague recall that athletes have funny ECGs and echos.

The practice of sports cardiology requires a knowledge of cardiac imaging, clinical electrophysiology and inherited heart disease superimposed with an appreciation of exercise physiology. Moreover, like all fields of cardiology, expertise is acquired through practice and observation. There are established dedicated sports cardiology courses and training programs in Europe and the United States. As a rapidly evolving field, we are interested to assess what the demand might be for a structured program in Australasia.

We have developed dedicated specialised sports cardiology services in Sydney and Melbourne and are aware of several specialists around Australia and New Zealand who have a dedicated interest and expertise. We believe that it is timely to form an interest group within CSANZ to assess demand for training and dedicated service provision whilst also providing a forum for discussing interesting cases and progress within this niche field. We invite any interested parties to contact us as we seek to establish the CSANZ working group for sports cardiology.

Prof Bruce Neal presented his SSaSS at the ESC Congress

Prof Bruce Neal is Executive Director at The George Institute for Global Health Australia; and Professor of Medicine, UNSW Sydney. Prof Neal presented his SSaSS study at the ESC Congress 2021.

SSaSS: Salt Substitute and Stroke Study into the effect of salt substitutes on cardiovascular events and death was presented by Prof Bruce Neal can be viewed here on ESCTV link:  https://www.escardio.org/Congresses-&-Events/ESC-Congress/Congress-news?section=esctv#esctv

 link to  YouTube  https://www.youtube.com/watch?v=O7WIomwOwDs&t=31s

Prof Nicholls says “We CAN stabilise plaques after an ACS”

We were excited to see a lot of CSANZ presenters at this year’s ESC Cardiology Conference held over the past 3 days 27 – 30 August 2021. Also featured – in the Late Breaking Trials was Monash University and Victorian Heart Institute’s Director, (and CSANZ President elect) Prof Stephen Nicholls presenting the novel findings of the HUYGENS Study.
This research shows that treatment with high dose statins and Evolocumab stabilises vulnerable plaque in one year.

Prof Nicholls says “We CAN stabilise plaques after an ACS”

Prof Chris Semsarian presented at the ESC Congress Digital 2021

Prof Chris Semsarian presented at the 2021 ESC Congress last weekend.  Chris was part of the panel, Meet the Experts: sudden cardiac death in the patient with an apparent normal heart.  His presentation was very well received and discussed, it was a multi approach to arrive to a correct diagnosis of Sudden Cardiac Death in the patient with an apparently normal heart.

 

 

Posts navigation